In our study of TAC mice treated with inhibitors in vivo, we found that no matter LY294002, an inhibitor of the PI3K/AKT signaling pathway, or Venetoclax, a selective Bcl-2 inhibitor, protected against cardiac hypertrophy. Here, AKT1 is linked to cardiac hypertrophy.